Molecular cancer, 2021-11, Vol.20 (1), p.151-151, Article 151
2021
Volltextzugriff (PDF)
Details
- Autor(en) / Beteiligte
- Titel
- Liquid biopsy identifies actionable dynamic predictors of resistance to Trastuzumab Emtansine (T-DM1) in advanced HER2-positive breast cancer
- Ist Teil von
- Molecular cancer, 2021-11, Vol.20 (1), p.151-151, Article 151
- Ort / Verlag
- England: BioMed Central Ltd
- Erscheinungsjahr
- 2021
- Quelle
- MEDLINE
- Beschreibungen/Notizen
- Keywords: HER2.sup.+ breast cancer, T-DM1, Liquid biopsy, Circulating tumor DNA, Pharmacological resistance
- Sprache
- Englisch
- Identifikatoren
- ISSN: 1476-4598eISSN: 1476-4598DOI: 10.1186/s12943-021-01438-zTitel-ID: cdi_doaj_primary_oai_doaj_org_article_bd5df440505045f68ad0544ebd6f26e2
- Format
- –
- Schlagworte
- Ado-Trastuzumab Emtansine - pharmacology, Ado-Trastuzumab Emtansine - therapeutic use, Adult, Aged, Aged, 80 and over, Antimitotic agents, Antineoplastic agents, Biomarkers, Tumor, Biopsy, Breast cancer, Breast Neoplasms - diagnosis, Breast Neoplasms - drug therapy, Breast Neoplasms - etiology, Cancer, Cancer therapies, Care and treatment, Circulating tumor DNA, Development and progression, Disease Progression, Drug Resistance, Neoplasm - genetics, ErbB-2 protein, Female, Gene Amplification, HER2+ breast cancer, Humans, Letter to the Editor, Leukocytes (mononuclear), Liquid biopsy, Liquid Biopsy - methods, Middle Aged, Mutation, Neoplasm Grading, Neoplasm Staging, Patients, Peripheral blood mononuclear cells, Pharmacological resistance, Plasma, Prognosis, Receptor, ErbB-2 - genetics, Receptor, ErbB-2 - metabolism, T-DM1, Trastuzumab, Trends, Tumors